Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
42 hedge funds and large institutions have $139M invested in Avadel Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 14 closing their positions.
136% more call options, than puts
Call options by funds: $3.79M | Put options by funds: $1.61M
72% more capital invested
Capital invested by funds: $80.6M → $139M (+$58.2M)
25% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 8
2.77% less ownership
Funds ownership: 51.85% → 49.08% (-2.8%)
5% less funds holding
Funds holding: 44 → 42 (-2)
14% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 14
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$18M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$8.58M |
| 3 |
GJL
Gendell Jeffrey L
|
+$4.1M |
| 4 |
Millennium Management
New York
|
+$2.69M |
| 5 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$1.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIP
Brandes Investment Partners
La Jolla,
California
|
-$13.4M |
| 2 |
DM
Deerfield Management
New York
|
-$11.3M |
| 3 |
BC
Broadfin Capital
New York
|
-$11M |
| 4 |
JAM
JW Asset Management
Miami Beach,
Florida
|
-$1.85M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.5M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$42K | -10,000 | Closed |
|
52
Acadian Asset Management
Boston,
Massachusetts
| – | -$35K | -8,372 | Closed |
|
|
TRCT
53
Tower Research Capital (TRC)
New York
| – | -$3K | -765 | Closed |
|
54
US Bancorp
Minneapolis,
Minnesota
| – | -$1K | -364 | Closed |
|
AVDL Hedge Fund Activity: Q4 2019 in Review
42 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q4 2019, worth a combined $139M — up 72% from $80.6M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of AVDL and 12 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 10 added.
The largest buyer was RTW Investments, opening a new position worth an estimated $18M. The largest seller was Brandes Investment Partners, cutting an estimated $13.4M.
- 42 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q4 2019, down from 44 in Q3 2019.
- Funds reported $139M of Avadel Pharmaceuticals stock for Q4 2019, up 72% quarter-over-quarter.
- 12 funds opened new Avadel Pharmaceuticals positions in Q4 2019 and 14 closed out, a net change of -2 holders.
- The largest Avadel Pharmaceuticals buyer in Q4 2019 was RTW Investments, an estimated $18M added.
- The largest Avadel Pharmaceuticals seller in Q4 2019 was Brandes Investment Partners, an estimated $13.4M sold.
Based on aggregated 13F filings for Q4 2019.